ABSTRACT
additional 2-3 days (i.e. from day 3 to day 5-6), embryo self-selection will occur after activation of the embryonic genome on day 3. This, in turn, enables identification of those embryos capable of forming blastocysts in vitro and so, theoretically, should enable selection of those with the highest implantation potential [2] [3] [4] . Thus, blastocyst transfer may increase the pregnancy rate per embryo transferred, which is especially relevant in the context of single embryo transfer policies intended to reduce multiple gestations 5, 6 .
Despite the above potential advantages of extended culture, there are also some theoretical disadvantages. First, it is likely that the in-vitro environment is inferior to that in vivo, which may lead to some embryos failing to blastulate in culture that would have implanted successfully if transferred at the cleavage stage 7, 8 . Second, in-vitro culture beyond embryonic genomic activation could potentially harm the embryo. Indeed, several studies have shown an increased incidence of transfer cancellation and a lower number of embryos cryopreserved in association with blastocyst-stage transfer.
This review was initiated to support the World Health Organization in the development of its global guidance for best practice in the field of assisted reproduction. For this field, effectiveness is associated with the improvement in the likelihood of having a live birth, while safety is associated with the health of the child and mother, and so relates to adverse effects. Both concepts of effectiveness and safety must be assessed and summarized to permit evidence-based decisions in clinical practice 9 . The present review is focused on assessing the effectiveness of blastocyst transfer vs cleavage-stage embryo transfer on the clinical outcomes of women undergoing IVF/intracytoplasmic sperm injection (ICSI) cycles. In consideration of lower resource settings, effectiveness is critical to support global recommendations of the best standard of care that will ensure a desired live birth for couples and individuals often attempting to overcome a highly stigmatizing status of involuntary childlessness.
METHODS

Protocol and registration
This systematic review was registered at PROSPERO in June 2015 (registration number: CRD42015023910 https://www.crd.york.ac.uk/PROSPERO).
Eligibility criteria
We included randomized controlled trials (RCTs) comparing the transfer of blastocysts (days [5] [6] with the transfer of cleavage-stage embryos (days 2-3) in women undergoing IVF/ICSI. Studies published only as abstracts and non-randomized studies were not considered eligible for inclusion in the main analyses as they are associated with a high risk of bias. In addition, because the number of embryos transferred may impact clinical outcome, studies in which there was a mean difference (MD) between the two groups of > 0.5 for number of embryos transferred were also excluded.
The following outcomes were assessed: ongoing pregnancy/live birth (primary), clinical pregnancy, cumulative pregnancy, miscarriage per clinical pregnancy, women with surplus frozen embryos and number of cryopreserved embryos. We preferentially used live birth, but when this was not reported, we used data reported for ongoing pregnancy, providing this related to viable pregnancy to at least 12 weeks' gestation. Ongoing pregnancy is considered as a primary outcome for effectiveness, and by not including data from these studies, only a partial view of the available evidence would have been represented [10] [11] [12] .
Information sources and searches
Searches of electronic databases PubMed and Scopus were performed. Additionally, the reference lists of included studies and related reviews were hand-searched to identify articles not captured by the electronic searches. There was no limitation regarding language or publication date.
The following search terms were used: (embryo*) AND (cleav* OR 'day 2' OR 'day 3') AND (blastoc* OR 'day 5' OR 'day 6') AND (RCT OR random* OR crossover OR trial). The last electronic search was run on 1 August 2016. Titles and abstracts retrieved by the searches were screened independently by two authors (W.P.M. and C.O.N.), checking for duplicates and using the pre-established criteria for inclusion. The same two authors further examined the full-text articles, making every attempt to avoid inclusion of studies with the same or overlapping populations. Disagreements were resolved by discussion.
Data collection process
Data extraction was performed independently by two authors (W.P.M. and C.O.N.) using a data-extraction form designed and pilot-tested by the authors. Where ongoing pregnancy was not reported, but both clinical pregnancy and miscarriage were, we calculated ongoing pregnancy as the number of clinical pregnancies at or beyond 12 weeks' gestation minus the number of miscarriages. If necessary, we corresponded with study investigators in order to solve any query. Disagreements were resolved by discussion.
Risk of bias in individual studies
Two authors (W.P.M. and C.O.N.) assessed independently the risk of bias in the included studies. The risk of bias of the RCTs was assessed using the Cochrane Collaboration's criteria for judging risk of bias 13 : the trials were classified as being of 'low', 'high' or 'unclear' risk of bias. We did not consider that blinding was likely to influence the risk of performance and detection bias for the reproductive outcomes. 
Summary measures and synthesis of results
Dichotomous variables were summarized by the risk ratio (RR) and continuous outcomes by MD; precision of the estimates was evaluated by 95% CIs. We considered the clinical relevance of all comparisons by taking into account the precision of the estimates. Where a significant difference was observed, we determined the number needed to treat for an additional beneficial (NNTB) or harmful (NNTH) outcome. The random-effects model was chosen because the true effect size should not be assumed to be the same across studies; additionally, the random-effects model incorporates the observed heterogeneity among studies, obtaining more conservative CIs [14] [15] [16] . Heterogeneity was assessed by the I 2 statistic; wherever it was moderate (I 2 > 30%) or substantial (I 2 > 50%), we explored the possible explanations by conducting subgroup analyses, sensitivity analyses and cumulative meta-analyses. Any statistical heterogeneity was taken into account when interpreting the results and grading the quality of the evidence, especially if there was any variation in the direction of the effect.
Risk of bias across studies
In view of the difficulty of detecting and correcting for publication and other reporting biases, the authors tried to minimize their potential impact by ensuring a comprehensive search for eligible studies and by being alert to the duplication of data. We performed funnel-plot analysis for ongoing pregnancy/live birth and clinical pregnancy to investigate whether the results from small/imprecise studies were more likely to be on the same side of the estimate as the larger/precise studies, which is suggestive of publication bias 13 .
Other analyses
We performed sensitivity analyses to evaluate whether the conclusions would have differed if (1) eligibility had been restricted to RCTs deemed at low risk of bias, (2) evidence had also been included from studies published only as abstracts and (3) studies had been included regardless of the policy for number of embryos transferred.
The following subgroup analyses were performed for ongoing pregnancy/live birth: (1) number of embryos transferred (1; 2; > 2 allowed); (2) 38 Coskun (2000) 39 Emiliani (2003) 40 Fernández-Shaw (2015) 49 Hreinsson (2004) 41 Kolibianakis (2004) 43 Papanikolaou (2005) 46 Papanikolaou (2006) 45 Rienzi (2002) 47 Van der Auwera (2002) 
Study or subgroup
Bungum (2003) 38 Coskun (2000) 39 Emiliani (2003) 40 Fernández-Shaw (2015) 49 Hreinsson (2004) 41 Kolibianakis (2004) 43 Montag (2006) 44 Kaur (2014) 42 Papanikolaou (2005) 46 Papanikolaou (2006) 45 Rienzi (2002) 47 Van der Auwera (2002) (low; atmospheric; unclear), (3) woman's age (mean age ≤ 33 years; unselected); (4) number and quality of available embryos at inclusion (at least four zygotes (day 1); at least three good-quality day 2 or 3 embryos; other studies). One additional subgroup analysis was performed stratifying studies that reported only ongoing pregnancy and those that reported live birth.
We also performed cumulative meta-analyses for ongoing pregnancy/live birth and for clinical pregnancy in order to examine whether there was a trend in the change in magnitude of effect over time (possibly due to the recent trend towards improved culture technologies). This is an analysis of great importance globally, as newly established public and private healthcare systems begin to establish some of their first IVF centers and attempt to determine which culture technologies to adopt within their fertility care services.
RESULTS
Study selection
A total of 1187 records were retrieved: PubMed, n = 521; Scopus, n = 658; hand-searching reference list of retrieved studies, n = 8. Of these, 323 were duplicates and 831 clearly did not meet the inclusion Coskun (2000) 39 Emiliani (2003) 40 Fernández-Shaw (2015) 49 Hreinsson (2004) 41 Kolibianakis (2004) 43 Papanikolaou (2005) criteria and were excluded. From the 33 potentially eligible studies, 21 were excluded: four because they were pseudorandomized [17] [18] [19] [20] , nine because they were published only as abstracts [21] [22] [23] [24] [25] [26] [27] [28] [29] , seven because the embryo-transfer policy was different for the two study groups [30] [31] [32] [33] [34] [35] [36] and one because of inconsistent results 37 . The remaining 12 studies [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] , including 1200 women undergoing blastocyst transfer and 1218 undergoing cleavage-stage transfer, were included in this review.
Study characteristics and risk of bias
The main characteristics and assessment for risk of bias of the 12 included studies are presented in Table 1 .
Results of individual studies
The results of individual studies are reported in the forest plots (Figures 1-6 ).
Synthesis of results
The pooled results and judgment of the quality of the evidence for all assessed outcomes are shown in Table 2 . No significant differences were observed between blastocyst and cleavage-stage transfer for ongoing/live birth, clinical pregnancy, miscarriage or cumulative pregnancy rates. However, blastocyst transfer was associated with fewer patients having embryos frozen, as compared with cleavage-stage embryo transfer.
Risk of bias across studies
The funnel-plot analysis for ongoing pregnancy/live birth ( Figure 7) does not suggest any small-study effect. Cumulative meta-analysis for ongoing pregnancy/live birth and for clinical pregnancy showed no clear trend regarding a change in the magnitude of effect over time ( Figures S1 and S2) . Copyright 38 Fernández-Shaw (2015) 49 Kolibianakis (2004) 43 Van der Auwera (2002) 48 38 Fernández-Shaw (2015) 49 Kolibianakis (2004) 
Additional analyses
Subgroup analyses were not able to explain the observed heterogeneity and/or identify a specific subgroup that contributed either a larger or a smaller benefit following blastocyst-stage embryo transfer. The sensitivity analysis restricting eligibility to RCTs deemed to be at low risk of bias is also reported in Table 2 .
The results from sensitivity analyses, including evidence from abstracts, did not alter the direction or magnitude of the observed effects: no significant differences were observed for ongoing pregnancy/live birth (18 studies, 2703 participants; RR, 1.14 (95% CI, 0.96-1.35), lowquality evidence), clinical pregnancy (28 studies, 4486 participants; RR, 1.10 (95% CI, 0.98-1.24), low-quality evidence), miscarriage (19 studies, 1132 pregnancies; RR, 1.06 (95% CI, 0.77-1.46), low-quality evidence), or cumulative pregnancy (eight studies, 631 participants; RR, 0.89 (95% CI, 0.71-1.11), low-quality evidence). Consistent with the analyses that excluded data from abstract publications, fewer women had surplus embryos frozen following blastocyst transfer (eight studies, 1473 participants; RR, 0.74 (95% CI, 0.65-0.84), moderate-quality evidence).
The subgroup analysis separating studies reporting live birth (four studies, 742 participants; RR, 1.35 (95% CI, 1.05-1.74)) from those reporting only ongoing pregnancy (six studies, 1198 participants; RR, 0.98 (95% CI, 0.79-1.22)) is shown in Figure S3 .
DISCUSSION
Although our confidence in the effect estimate is limited, we did not observe any difference in live birth/ongoing pregnancy, clinical pregnancy, miscarriage or cumulative pregnancy when comparing the transfer of blastocysts against the transfer of cleavage-stage embryos. We are, however, moderately confident that the transfer of blastocyst-stage embryos results in fewer women with surplus embryos for a subsequent transfer ( Figure 5 ).
Limitations and quality of evidence
Although this review included a large number of studies and participants, our confidence in the body of evidence was compromised by some important issues. First, only three 38, 39, 41 of the 12 included RCTs were judged to be at low risk of bias. The remaining nine RCTs were deemed to be at high risk of bias for at least one reason. The majority of studies evaluating cumulative pregnancy did not follow up women until all frozen embryos had been transferred or a pregnancy achieved. Because of this, the quality of the evidence for all outcomes was downgraded one level.
The second reason for downgrading the quality of the evidence was the important and unexplained inconsistency observed across the included studies. This inconsistency was not only observed as heterogeneity across the studies (high I 2 ) but also as a difference in Table 2 Pooled results for reproductive outcomes and quality of evidence (QoE) of randomized controlled trials of women randomized to blastocyst-stage or cleavage-stage embryo transfer (ET)
All studies Sensitivity analysis* Outcome S (n) No studies None -Very low § § *Excluding studies judged to be at high risk of bias. †Mean difference (MD). ‡Relative risk (RR) > 1.0 suggests increased risk of outcome in women with blastocyst ET compared with women undergoing cleavage-stage ET. §Number needed to treat (NNT): number of women undergoing blastocyst ET to increase/decrease outcome by one additional event. ¶Downgraded one level because of quality of included studies. **Downgraded one level because of unexplained inconsistency. † †Downgraded one level because of serious imprecision. ‡ ‡Downgraded one level because of quality of included studies: majority of studies did not follow up women until all frozen embryos had been transferred or pregnancy achieved. § §Downgraded one level because of limitations of included studies and two levels because of serious inconsistency. E, events; LB, live birth; NS, non-significant; OP, ongoing pregnancy; P, participants; S, studies. the direction of the observed effect: while most of the studies showed no effect, some showed a significant benefit associated with blastocyst transfer and others showed significant harm. For the outcome of miscarriage, there was no important inconsistency; nevertheless, the serious imprecision observed led to the quality being downgraded by one level. For the proportion of women with surplus embryos cryopreserved, the quality of the evidence was downgraded two levels because of serious inconsistency; one study 49 reported that more embryos were cryopreserved in the blastocyst group. This finding appears to be at odds with the authors' claim that only 245/362 (68%) embryos reached blastocyst stage. It is most likely that the authors discarded a large proportion of the embryos at cleavage stage in the other group, but this is not reported clearly and would be an important source of bias. It is actually expected that women will have more embryos available for cryopreservation when transferring at cleavage stage, since only approximately half the embryos at the cleavage stage will achieve blastulation on days 5-6 in artificial culture (Table 1) .
Also noteworthy is the observation of a significant benefit among studies that reported live birth but not among studies that reported ongoing pregnancy ( Figure S3 ). This suggests that authors who observed a significant improvement on reproductive outcomes with blastocyst-stage embryo transfer were more likely to follow up the participants until live birth. While the funnel-plot analyses and cumulative meta-analyses did not raise suspicion of publication bias, this last subgroup analysis led us to suspect bias due to selective reporting, thereby explaining some of the heterogeneity observed in the live birth/ongoing pregnancy analysis (Figure 1 ).
Comparison with other systematic reviews
Three other reviews evaluating the difference between blastocyst and cleavage-stage embryo transfer were identified; all three, however, reflect a somewhat partial Copyright view of the body of evidence, as fewer studies were included. The last updated version of the Cochrane review assessing the effectiveness was published recently 5 . The authors of this review concluded that blastocyst-stage embryo transfer results in higher live birth and clinical pregnancy rates when compared with cleavage-stage embryos for fresh embryo transfer (low-quality evidence for live birth and moderate-quality evidence for clinical pregnancy). Although there was a difference in eligibility criteria, as they permitted the inclusion of studies at a higher risk of bias (different number of embryos transferred, studies published only as abstracts), the difference in the conclusions was not caused by the inclusion of different studies but, rather, by the different method used for meta-analysis. The Cochrane review used Peto odds ratio (fixed effect), while we used the RR determined by Mantel-Haenszel using a random-effects model, which we believe to be more appropriate (Appendix S1). If the authors of the Cochrane review had used the method we employed here, the estimates would be very similar ( Figures S4-S6) . Furthermore, although the difference in the estimates is not great, this observation highlights the fragility of the evidence of benefit. The result of another systematic review published in 2008 including evidence from six studies also showed a small benefit of blastocyst embryo transfer on live birth 50 . A more recently published systematic review 6 also identified a benefit on live birth and clinical pregnancy with blastocyst transfer, but this review included only six studies evaluating fewer than 1500 women.
Aside from the different analytical approach used in the Cochrane review and the limited study inclusions in the two earlier studies, other factors may have contributed to the difference in findings we report here. The possibility exists that including only live birth and not including ongoing pregnancy as a surrogate might introduce bias in the review process, as authors of studies showing no difference in effect might become less motivated to follow up participants through to live birth 9 .
Conclusions
Current evidence shows no superiority of blastocyst transfer compared with cleavage-stage embryo transfer in clinical assisted reproductive techniques: there is low-quality evidence from RCTs that blastocyst transfer does not result in increased rates of ongoing pregnancy/live birth, clinical pregnancy, miscarriage or cumulative pregnancy, and there is moderate-quality evidence that it reduces the proportion of women with surplus embryos after transfer. As the quality of the evidence for the primary outcomes is low, additional well-designed RCTs are still needed before robust conclusions can be drawn.
One should still consider further issues regarding obstetric outcomes associated with blastocyst embryo transfer: the available evidence suggests an increased risk of perinatal mortality, preterm birth and delivery of a large-for-gestational-age neonate, with a reduced risk of delivery of a small-for-gestational-age neonate [51] [52] [53] .
Moreover, there are some considerations regarding the costs of offering extended culture to blastocyst stage, which are particularly important considering accessibility in lower-resource settings. Therefore, before considering a change in clinical practice, any potential benefit of the intervention should be weighed against possible worse neonatal outcomes and increased costs.
SUPPORTING INFORMATION ON THE INTERNET
Appendix S1 Problems with analysis using the Peto odds ratio Figure S1 Cumulative meta-analyses for live birth/ongoing pregnancy in women randomized to blastocyst-stage embryo transfer on days 5-6 or cleavage-stage embryo transfer on days 2-3. RR, risk ratio. Comparación entre la etapa de blastocisto y la etapa de escisión en la transferencia embrionaria: revisión sistemática y metaanálisis de los resultados reproductivos RESUMEN Objetivos La transferencia de blastocistos en técnicas de reproducción asistida podría ser ventajosa porque el momento en que se expone el embrión al ambiente uterino es más parecido al de un ciclo natural y permite la autoselección del embrión después de la activación del genoma embrionario en el día 3. Por el contrario, el ambiente in vitro es probablemente peor que el ambiente in vivo, y el cultivo in vitro más allá del momento de la activación genómica embrionaria podría potencialmente dañar el embrión. Nuestro objetivo fue identificar, evaluar y resumir la evidencia disponible que compara la eficacia de la transferencia de embriones en la etapa de blastocisto con la etapa de escisión.
MétodosÉsta fue una revisión sistemática y metaanálisis de ensayos controlados aleatorizados (ECA) en los que se compara la transferencia de blastocistos (días 5-6) con la transferencia de embriones en etapa de escisión (días 2-3) en mujeres sometidas a fertilización in vitro o una inyección intracitoplasmática de espermatozoides. Lasúltimas búsquedas electrónicas se realizaron el 1 de agosto de 2016. Se excluyeron los resúmenes y los estudios con una diferencia promedio entre los dos grupos de estudio > 0,5 para el número de embriones transferidos.
